Erlotinib efficacy as first-line treatment for patients with advanced EGFR mutation-positive non-small-cell lung cancer

Summary. In a prospective, randomized, controlled phase III study EURTAC was shown, that the use of the erlotinib in the first-line treatment of patients of the European population with advanced non-small cell lung cancer (NSCLC), and tumors that have mutations that activate EGFR, almost double the rate of progression-free survival. These data are similar to the results of the phase III study OPTIMAL, which included patients with the same form of NSCLC, related to the Asian population.
Follow us on social media:
No Comments » Add your
Leave a comment